Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain

Anesthesiology

Volumn 102, Issue 1, 2005, Pages 132-140

  Donovan Rodriguez, Tansy ^a   Dickenson, Anthony H ^a   Urch, Catherine E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BONE PAIN; CANCER; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHYSIOLOGY; LONG TERM CARE; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; SPINAL CORD DORSAL HORN; SPINAL CORD NERVE CELL;

AMINES; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; CELL LINE, TUMOR; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; GAMMA-AMINOBUTYRIC ACID; MALE; NEOPLASM TRANSPLANTATION; NEURONS; OSTEOTOMY; PAIN; PAIN MEASUREMENT; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; TEMPERATURE;

EID: 11444252737     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200501000-00022     Document Type: Article

References (45)

1. Coyle N, Adelhardt J, Foley KM, Portenoy RK: Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990; 5:83-93
2. Mercadante S: Malignant bone pain: Pathophysiology and treatment. Pain 1997; 69:1-18
3. Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain 1999; 81:129-34
4. Tubiana-Hulin M: Incidence, prevalence and distribution of bone metastases. Bone 1991; 12 Suppl 1:S9-10
5. Mercadante S, Arcuri E: Breakthrough pain in cancer patients: Pathophysiology and treatment. Cancer Treat Rev 1998; 24:425-32
6. Clohisy DR, Mantyh PW: Bone cancer pain. Cancer 2003; 97:866-73
7. Mercadante S, Maddaloni S, Roccella S, Salvaggio, L: Predictive factors in advanced cancer pain. Pain 1992; 50:151-5
8. Bruera E, Schoeller R, Wenk R, MacEachern T, Marcelino S, Hanson J, Suarez-Almozor M: A prospective multi-center assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995; 10:348-55
9. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW: Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999; 19:10886-97
10. Medhurst SJ, Walker K, Bowes M, Kidd BL., Glatt, M., Muller, M, Hattenberger, M, Vaxelaire, J, O'Reilly, T, Wotherspoon, G, Winter, J, Green, J, Urban, L: A rat model of bone cancer pain. Pain 2002; 96:129-40
11. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW: Different tumours in bone each give rise to a distinct pattern of skeletal bone destruction, bone cancer-related pain behaviours and neurochemical changes in the central nervous system. Int J Cancer 2003; 104:550-8
12. Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ, Wilcox GL: Tumour implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain 2003; 101:175-86
13. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurones. Neurosci 2000; 98:585-98
14. Urch CE, Donovan-Rodríguez T, Dickenson AH: Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain 2003; 106:347-56
15. Donovan-Rodriguez T, Dickenson AH, Urch CE: Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neurosci Lett 2004; 360:29-32
16. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP: Mechanisms of cancer pain. Nat Rev Cancer 2002; 2:201-9
17. Stanfa LC, Singh L, Williams RG, Dickenson AH: Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport 1997; 8:587-90
18. Chapman V, Suzuki R, Chamarette HL, Rygh LJ, Dickenson AH: Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain 1998; 75:261-72
19. Matthews EA, Dickenson AH: A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. ANESTHESIOLOGY 2002; 96:633-40
20. Levendoglu F, Ogun CO, Ozerbil O, Ogiun TC, Ugurlu H: Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004; 29:743-51
21. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW: Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain. Pain 2002; 99:397-406
22. Christensen D, Gautron M, Guilbaud G, Kayser V: Effect of gabapentin and lamotrigine on mechanical allodynia-like behaviour in a rat model of trigeminal neuropathic pain. Pain 2001; 93:147-53
23. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH: Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 2002; 5:1319-26
24. Goa KL, Sorkin EM: Gabapentin: A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46:409-27
25. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29:233-49
26. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271:5768-76
27. Chaplan SR, Pogrel JW, Yaksh TL: Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994; 3:1117-23
28. Malmberg AB, Yaksh TL: Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type calcium channels inhibits formalin-induced nociception. J Neurosci 1994; 14:4882-90
29. Diaz A, Dickenson AH: Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain 1997; 69:93-100
30. Matthews EA, Dickenson AH: Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 2001; 92:235-46
31. Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova J, Yaksh TL: Localization of N-type calcium channels in the rat spinal cord following chronic constriction nerve injury. Exp Brain Res 2002; 147:456-63
32. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL: Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001; 21:1868-75
33. Griffiths JR: Are cancer cells acidic? Br J Cancer 1991; 64:425-7
34. Suzuki K, Yamada S: Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone resorbing factors including transforming growth factor alpha, interleukin 1 alpha and interleukin 6. Bone Miner 1994; 27:219-33
35. Watkins LR, Wiertelak EP, Furness LE, Maier SF: Illness-induced hyperalgesia is mediated by spinal neuropeptides and excitatory amino acids. Brain Res 1994; 664:17-24
36. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S: Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha. Br J Pharmacol 1997; 121:417-24
37. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, Fontana DJ: The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997; 324:153-60
38. Abdi S, Lee DH, Chung JM: The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998; 87:1360-6
39. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L: Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997; 121:1513-22
40. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi F, Yamaguchi T: Allodynia and hyperalgesia in adjuvant-induced arthritic rats: Time-course of their progression and efficacy of analgesics for them. J Pharmacol Exp Ther 2003; 306:490-7
41. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, Rondelli I, Chamiot-Clerc P, Simonato M, Barbiert M: Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist CHF3381 in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003; 306:804-14
42. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D: Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: A pilot study. Eur Neurol 1998; 40:191-200
43. Werner MU, Perkins FM, Holte K, Pedersen JL, Kehlet H: Effects of gabapentin in acute inflammatory pain in humans. Reg Anesth Pain Med 2001; 26:322-8
44. Partridge BJ, Chaplan SR, Sakamoto E, Yaksh TL: Characterization of the effects of gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia. ANESTHESIOLOGY 1998; 88:196-205
45. Cho HS, Kim MH, Choi DH, Lee JI, Gwak MS, Hahm TS: The effect of intrathecal gabapentin on mechanical and thermal hyperalgesia in neuropathic rats induced by spinal nerve ligation. J Korean Med Sci 2002; 17:225-9